BamSEC and AlphaSense Join Forces
Learn More
You must log in to view this page.

Supernus Pharmaceuticals Inc. – Material Contracts

NASDAQ: SUPN    
Share price (6/5/26): $44.75    
Market cap (6/5/26): $2.597 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 3 pages Certain Confidential Information Identified in This Document Marked by *** , Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.2
from 10-Q 16 pages Material contract
12/34/56
EX-10.1
from 10-Q 6 pages Material contract
12/34/56
EX-10.1
from 8-K 23 pages Cvr Agreement
12/34/56
EX-10.3
from 8-K 8 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Performance Share Unit Award Agreement
12/34/56
EX-10.1
from 10-Q 52 pages Settlement Agreement by and Between Supernus Pharmaceuticals, Inc. and Ascent Pharmaceuticals, Inc. Dated as of April 30, 2024
12/34/56
EX-10.48
from 10-K 33 pages Settlement Agreement by and Between Supernus Pharmaceuticals, Inc. and Apotex Inc. Apotex Corp. Dated as of June 21, 2023
12/34/56
EX-10.44
from 10-K 7 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Performance Share Unit Award Agreement
12/34/56
EX-10.42
from 10-K 5 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Restricted Stock Unit Agreement Supernus Pharmaceuticals, Inc. Strongly Encourages You to Seek the Advice of Your Own Legal and Financial Advisors With Respect to Your Award and Its Tax Consequences
12/34/56
EX-10.40
from 10-K 4 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Supernus Pharmaceuticals, Inc. Strongly Encourages You to Seek the Advice of Your Own Legal and Financial Advisors With Respect to Your Award and Its Tax Consequences. Form of Non-Statutory Time-Based Stock Option Agreement
12/34/56
EX-10.38
from 10-K 4 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Supernus Pharmaceuticals, Inc. Strongly Encourages You to Seek the Advice of Your Own Legal and Financial Advisors With Respect to Your Award and Its Tax Consequences. Form of Time-Based Incentive Stock Option Agreement
12/34/56
EX-10.16
from 10-K 9 pages Form of Executive Retention Agreement
12/34/56
EX-10.71
from 10-K 34 pages Settlement Agreement by and Between Supernus Pharmaceuticals, Inc. and Zydus Pharmaceutical (USA) Inc. Zydus Lifesciences Limited Dated as of December 31, 2022
12/34/56
EX-10.1
from 8-K 21 pages Certain Confidential Information Identified in This Document, Marked by [*], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.1
from 10-Q 5 pages Amendment to Deed of Lease
12/34/56
EX-10.6
from 10-Q 7 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Performance Share Unit Award Agreement
12/34/56
EX-10.5
from 10-Q 4 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.4
from 10-Q 4 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Supernus Pharmaceuticals, Inc. Strongly Encourages You to Seek the Advice of Your Own Legal and Financial Advisors With Respect to Your Award and Its Tax Consequences. Form of Non-Statutory Time-Based Stock Option Agreement
12/34/56
EX-10.3
from 10-Q 4 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Supernus Pharmaceuticals, Inc. Strongly Encourages You to Seek the Advice of Your Own Legal and Financial Advisors With Respect to Your Award and Its Tax Consequences. Form of Time-Based Incentive Stock Option Agreement
12/34/56
EX-10.2
from 10-Q 34 pages Certain Confidential Information Identified in This Document, Marked by [**], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Api Supply Agreement
12/34/56